MELISSA KOBITO: Open Payments
NPI 1912690793 · NEW HARTFORD, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,276 in 192 payments from 18 companies in 2025. Trend: 2023 $570 · 2024 $1,046 · 2025 $3,276
Food & beverage: $3,266Education: $10
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 37 | $620 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 65 | $583 |
| Janssen Biotech, Inc. | 18 | $484 |
| Madrigal Pharmaceuticals | 11 | $420 |
| Ardelyx, Inc. | 7 | $184 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $180 |
| Aimmune Therapeutics, Inc. | 6 | $123 |
| PFIZER INC. | 6 | $103 |
| Celltrion USA Inc. | 6 | $103 |
| Ipsen Biopharmaceuticals, Inc | 3 | $88 |
Products named: XIFAXAN, TREMFYA, REZDIFFRA, RINVOQ, IBSRELA, LINZESS, ENTYVIO, VEGZELMA.
Industry payments across NY — which companies pay providers there.
